Diaceutics PLC (AIM: DXRX) — Investment Research Note

Executive summary

Diaceutics is a precision-medicine commercialisation platform (DXRX) that aggregates diagnostic-lab, claims and physician data and resells AI-derived "where are eligible patients?" insights to global pharma — it currently works with 18 of the world's top 20 pharma companies across 95 therapeutic brands. The trajectory across the 5-year filing window is one of a sub-scale consulting business successfully repositioning to a recurring-revenue platform: revenue grew from £13.9m (FY21) to £38.4m (FY25), ARR mix is now £20.0m, and the business returned to profitability in FY25 with adjusted EBITDA expanding from £4.2m to £7.6m on 20% revenue growth — a classic operating-leverage inflection. The single most important point for valuation today is whether the FY26 outlook (25% growth target / Q1 ran at +15% cc) reflects normal phasing or genuine deceleration: at ~£140m mcap the platform thesis is partially in the price, but not heroically so.

Fair value estimate

Methodology: Forward EV/EBITDA + EV/Sales triangulation on FY26E. DCF is impractical given short profit history.

Assumptions:

• FY26 revenue: £45-48m (CEO guides 25%; Q1 cc +15% gives a more cautious £45m floor) 2026-05 final results
• FY26 Adj EBITDA: £9.5-11.5m (20-24% margin, with continued operating leverage)
• Net cash ~£7m, no debt
• Peer multiples: vertical SaaS / data businesses 12-18x EBITDA, 3-5x sales

Fair value range: 165p – 224p, midpoint ~195p; implied mcap £140m – £190m. Current mcap £140.5m sits at the low end. Upside to midpoint: ~+33%; downside to low: ~0%. View: fair-to-modestly-undervalued.

Sector context

Confirmed ICB Health Care, but the operating model is closer to vertical-SaaS / pharma-tech than a typical healthcare equipment or services business. Quality (recurring revenue, gross margin) is above typical AIM healthcare peers; growth in line with US-listed pharma-data peers; balance sheet is below peers (cash declining, no debt). Closest listed comparators: Tempus AI (US, larger, multi-omics, mentioned explicitly in the FY25 report as a model), Evotec/Phastar (CRO-adjacent), and Trustpilot/Craneware as UK/AIM SaaS comps for multiple anchoring.

Investment thesis

• Recurring-revenue inflection is genuine. ARR grew from nil (FY20) to £20.0m (FY25); order book +56% YoY to £38.9m; 105% NRR; 18 of top 20 pharma customers — a moat-like footprint that has taken 5 years to assemble 2026-05 final results.
• Operating leverage is now visible. Adj EBITDA +80% on revenue +20%; margin expanded from 13% → 20% in one year; CFO explicitly attributes this to the platform model and flags continued AI-driven automation of data processing 2026-05 final results, 2026-01 trading update.
• Genuine AI-receiver positioning, not press-release AI. DXRX is a proprietary-data platform applying AI/ML for data ingestion, cohort refinement and signal detection; "agentic AI" capability is being built into the patient-pathway workflow — value capture lies with DXRX, not the model providers 2026-05 CEO review.

Key risks

• Cash burn and working capital stress. Cash fell 42% YoY to £7.3m at FY25 (vs £12.7m FY24, £19.7m FY21); receivables/accrued revenue ballooned to £19.7m as top-20 pharma extended payment terms; flat at Q1 2026 despite collections. Only a £2m undrawn overdraft sits behind it 2026-05 final results CFO review.
• Growth deceleration / FY26 risk. FY25 revenue (£38.4m) missed analyst consensus (£39.0-40.2m); Q1 2026 constant-currency growth slowed to 15% vs full-year FY25 24%. Management still guides 25% FY26 2026-01 trading update, 2026-05 final results.
• Customer concentration & US dependency. Single customer = 18% of FY25 revenue (FY24: 15%); 93% US-based; pharma budget discipline directly hits Diaceutics' top line — already cited as headwind in FY25 2026-05 final results note 4.

Operating leverage

The fixed-cost base is substantial: total employee costs £21m (FY25, broadly flat YoY despite +20% revenue), intangible amortisation £5.4m, and ongoing platform/data capex of ~£10m/year capitalised. Gross margin at 82% (down from 88% on FY25 data-cost step-up, expected to normalise) is software-like. The FY25 result is the cleanest demonstration of leverage: revenue +£6.3m, adj EBITDA +£3.4m — i.e. incremental contribution margin of ~54%, well above corporate average margin. Extrapolated, a 10-20% revenue beat on the FY26 base would plausibly add 40-80% to adjusted EBITDA. The PMx model (multi-year £5-13m contracts) is particularly potent because spend scales without proportional delivery cost once the platform is built 2026-05 final results CEO review.

Value-trap signals

• Cash declined every year of the filing window (£25m → £7m).
• FY25 revenue missed consensus despite EBITDA beat — quality of "beat" is partly a cost-control story.
• 12% growth in customer brands (95 vs 85) modest given 24% cc revenue — average revenue per brand only +2%.
• Heavy intangible capitalisation (data + platform additions £6.4m FY25) flatters EBITDA vs cash; cash conversion has weakened.
• Founder-family management (Peter & Ryan Keeling); related-party lease to O'Connor & McCann Ltd disclosed but immaterial.

Not a clear value trap — more "moderate accounting watch-items."

Earnings vs expectations

• FY21 (Mar-22): ahead of internal expectations; revenue +10% (+17% cc), Adj EBITDA £2.3m vs guidance — beat.
• FY22 (Jan-23 update): revenue ~£20m vs market expectation £16.3-16.8m — material beat.
• FY23 (Jan-24 update): revenue £23.7m, 22% growth — in line / modest beat.
• FY24 (Jan-25 update / May-25 results): revenue £32.2m (+39% cc), Adj EBITDA marginally ahead of consensus — beat.
• FY25 (Jan-26 / May-26): revenue £38.4m vs consensus £39.0-40.2m — revenue miss; Adj EBITDA £7.6m vs £6.9-7.3m — EBITDA beat.

Pattern: four consecutive beats followed by a quality-of-earnings inflection (cost discipline beat masked top-line softness) and a Q1-26 update showing growth more than halving on a constant-currency basis vs FY25. Mixed track record now.

Conviction

3 — moderate.

Anchors: (i) clean recurring-revenue disclosures (ARR, NRR, order book) give a reliable forward-revenue anchor; (ii) FY25 is the first full year of profitability so unit economics are observable; (iii) sector multiples for vertical pharma-data SaaS are well-established.

Limits: (i) decelerating Q1 26 vs guided FY26 growth — a 25% versus 15% gap materially shifts the EBITDA range; (ii) capitalised data/platform costs (~£10m/yr) flatter EBITDA vs cash, so "true" earnings power is debatable.

Driver scoring rationale (summary)

• AI beneficiary (60): proprietary diagnostic dataset + AI on top of it = vertical-SaaS AI-receiver, but it's pharma-budget-funded and pharma is currently cost-disciplined.
• Operating leverage (75): 82% GM, 54% incremental margin in FY25, ARR-led; not 80+ because cost base still scaling.
• Earnings surprise trend (50): 4 beats, then 1 mixed; trending toward in-line.
• Cyclicality (30): pharma R&D budgets cycle, but precision-medicine commercialisation is a secular driver.
• Moat (55): 18/20 pharma customers, multi-year data partnerships, lab network — narrow but real.
• Leverage (10): net cash, no debt — fortress-light.
• Earnings quality (50): heavy capitalisation, weakening cash conversion, ARR genuine — net moderate.
• Management quality (60): delivered platform transition; founder-family; no red flags but no exceptional capital allocation track record.
• Growth momentum (60): 20-24% delivered, decelerating to 15% in Q1; guide still 25%.